Search Result
Results for "
GGFG
" in MedChemExpress (MCE) Product Catalog:
-
- HY-13631E
-
Deruxtecan
Maximum Cited Publications
25 Publications Verification
MC-GGFG-DXD
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
|
-
-
- HY-114233
-
|
MC-GGFG-DX8951
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC) .
|
-
-
- HY-134723
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBCO-PEG4-GGFG-Dxd is a agent-linker conjugate for ADC with potent antitumor activity by using Dxd (a DNA topoisomerase I inhibitor), linked via the cleavable ADC linker DBCO-PEG4-GGFG . DBCO-PEG4-GGFG-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
-
- HY-153892
-
-
-
- HY-44246
-
|
Mc-GGFG-OH
|
ADC Linker
|
Cancer
|
|
MC-Gly-Gly-Phe-Gly is a cleavable ADC linker used for antibody-drug conjugates (ADCs).
|
-
-
- HY-153360
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .
|
-
-
- HY-158768
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Amino-PEG4-GGFG-Dxd (Compound 13-7) is a drug-linker conjugate for ADC. Amino-PEG4-GGFG-Dxd is composed of Dxd (HY-13631D) and a linker. Amino-PEG4-GGFG-Dxd can be used for synthesis of ADCs
|
-
-
- HY-156755
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Propargyl-PEG4-GGFG-DXd is a drug-linker conjugate for ADC. Propargyl-PEG4-GGFG-DXd contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D) .
|
-
-
- HY-P3669
-
|
|
ADC Linker
Drug Intermediate
|
Cancer
|
|
Gly-Gly-Phe-Gly is a peptide spacer and can be applied to Doxorubicin (HY-15142A) (DXR) conjugates. Gly-Gly-Phe-Gly can be used as an ADC linker to synthesize ADCs, such as Puxitatug samrotecan (AZD 8205) (HY-171689) .
|
-
-
- HY-P1449
-
|
|
ADC Linker
|
Cancer
|
|
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).
|
-
-
- HY-156848
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Fmoc-GGFG-DXd is a drug-linker conjugate for ADC. Fmoc-GGFG-DXd contains a ADC linker Fmoc-GGFG and a DNA topoisomerase I inhibitor DXd (HY-13631D) .
|
-
-
- HY-164788
-
-
-
- HY-13631EG
-
|
MC-GGFG-DXD
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
|
-
-
- HY-147363
-
|
|
Drug-Linker Conjugates for ADC
|
Others
|
|
DIBAC-GGFG-NH2CH2-Dxd (compound LP4), a Camptothecin (HY-16560) derivative, is a linker-payload of protein-agent conjugates . Dxd (HY-13631D) can be used as a payload for the antibody-coupling drug ADC (DS-8201a).DIBAC-GGFG-NH2CH2-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .
|
-
-
- HY-136432
-
|
Mc-GGFG-PAB-OH
|
ADC Linker
|
Cancer
|
|
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) is a cleavable ADC linker used for antibody-drug conjugates (ADCs).
|
-
-
- HY-13631ES4
-
-
-
- HY-P4192
-
|
|
ADC Linker
|
Cancer
|
|
Fomc-Gly-Gly-Phe-Gly-OH (compound D5) can be used as an intermediate in the synthesis of ADC dual-drug-linker. Fomc-Gly-Gly-Phe-Gly-OH synthetic intermediate GGFGE further forms an important ADC dual-drug link assembly unit .
|
-
-
- HY-153069
-
-
-
- HY-176415
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Cys-MC-GGFG-Dxd is a cysteine-modified, cleavable ADC drug-linker conjugate. Cys-MC-GGFG-Dxd consists of a maleimidocaproyl-glycine-glycine-L-phenylalanine-glycine (MC-GGFG) linker and an Exatecan (HY-13631) derivative (DXd) (HY-13631D) payload. Cys-MC-GGFG-Dxd can be further conjugated to anti-HER2 IgG1κ antibody for the synthesis of antibody-drug conjugates (ADC), such as the breast cancer-targeting ADC compound Fam-trastuzumab deruxtecan-nxki (Enhertu) .
|
-
-
- HY-157813
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan is a drug-linker conjugates for ADC, consiting of a cleavable linker and Exatecan (HY-13631). 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan can be linked to anti-Her3 antibody .
|
-
-
- HY-170512
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-GGFG-PAB-MMAE (Compound 8) is a drug-linker conjugate, which is composed of the mitotic inhibitor MMAE (HY-15162) and the linker Mal-GGFG-PAB. Mal-GGFG-PAB-MMAE can be used for synthesis of antibody-drug conjugate .
|
-
-
- HY-400770
-
|
1-(2-Amino-4-fluoro-5-methylphenyl)-2-chloroethanone
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-GGFG-AM-(10Me-11F-Camptothecin) intermediate-1 (compound 19-2) is an intermediate for the synthesis of MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360). Modifying groups can be added group. MC-GGFG-AM-(10Me-11F-Camptothecin) is a drug-linker conjugate used in the synthesis of ADCs .
|
-
-
- HY-177546
-
-
-
- HY-160807
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBM-GGFG-NH-O-CO-Exatecan (Example 4, Compound 14) is a conjugate of an ADC drug toxin molecule and a linker. DBM-GGFG-NH-O-CO-Exatecan is a complete antibody-drug conjugate intermediate that integrates a potent camptothecin-based toxin, a cleavable peptide linker (GGFG), and a reactive terminus that can directly conjugate to antibodies .
|
-
-
- HY-160967
-
-
-
- HY-156515
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is a drug-linker conjugate for ADC, formed by conjugation of 7ethanol-10NH2-11F-Camptothecin (HY-156517) with the protease-cleavable MC-GGFG linker. MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is applicable for cancer research .
|
-
-
- HY-153600
-
-
-
- HY-P11295
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-GGFG-PAB-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADC) .
|
-
-
- HY-128994A
-
|
|
Drug Intermediate
|
Cancer
|
|
GGFG-Exatecan TFA is a synthetic intermediate for drug-linker conjugates used in antibody-drug conjugates (ADCs). GGFG-Exatecan TFA consists of a glycyl-glycyl-phenylalanyl-glycine (GGFG) tetrapeptide linker and a DNA topoisomerase I inhibitor Exatecan (HY-13631). GGFG-Exatecan TFA can be used for the study of cancer .
|
-
-
- HY-13631ES3
-
|
MC-GGFG-DXD-d2
|
Drug-Linker Conjugates for ADC
Isotope-Labeled Compounds
|
Others
|
|
Deruxtecan-d2 is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
-
- HY-156687
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
GGFG-Eribulin (Compound GGFG) is a Drug-Linker Conjugates for ADC. GGFG-Eribulin consists of the ADC Cytotoxin Eribulin (HY-13442) and a linker. GGFG-Eribulin can be used for synthesis of ADCs .
|
-
-
- HY-171176
-
|
|
Drug-Linker Conjugates for ADC
|
Others
|
|
2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan is a drug-linker conjugate for ADC. 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan is composed of linker and Exatecan (HY-13631).
|
-
-
- HY-13631ES
-
-
-
- HY-45669
-
|
|
PROTAC Linkers
|
Cancer
|
|
Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Cbz is a PROTAC linker and a maleimide-GGFG peptide linker. Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Cbz can be used in the synthesis of the Deruxtecan .
|
-
-
- HY-128994
-
|
|
Drug Intermediate
|
Cancer
|
|
GGFG-Exatecan is a synthetic intermediate for drug-linker conjugates used in antibody-drug conjugates (ADCs). GGFG-Exatecan consists of a glycyl-glycyl-phenylalanyl-glycine (GGFG) tetrapeptide linker and a DNA topoisomerase I inhibitor Exatecan (HY-13631). GGFG-Exatecan can be used for the study of cancer .
|
-
-
- HY-156514
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-GGFG-AM-(10NH2-11F-Camptothecin) is an antibody drug conjugates (ADC). MC-GGFG-AM-(10NH2-11F-Camptothecin) binds to the anti-TROp-2 antibody sacituzumab via a hydrolysable pH-sensitive linker and has anti-tumor activity. MC-GGFG-AM-(10NH2-11F-Camptothecin) can be used for cancer research .
|
-
-
- HY-136432A
-
|
Mc-GGFG-PAB-OH TFA
|
ADC Linker
|
Cancer
|
|
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) TFA is a cleavable ADC linker used for antibody-drug conjugates (ADCs).
|
-
-
- HY-13631ES2
-
|
MC-GGFG-DXD-d4-1
|
Drug-Linker Conjugates for ADC
Isotope-Labeled Compounds
|
Others
|
|
Deruxtecan-d4-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
-
- HY-P1449A
-
|
|
ADC Linker
|
Cancer
|
|
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).
|
-
-
- HY-13631ES1
-
-
-
- HY-46346
-
|
|
PROTAC Linkers
|
Cancer
|
|
Fmoc-Gly-NH-CH2-O-CH2-Cbz is a PROTAC linker and a maleimide-GGFG peptide linker. Fmoc-Gly-NH-CH2-O-CH2-Cbz can be used in the synthesis of the Deruxtecan .
|
-
-
- HY-176415S
-
|
|
Isotope-Labeled Compounds
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Cys-MC-GGFG-Dxd-d5 is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd can be used in cancer research .
|
-
-
- HY-153069A
-
-
-
- HY-178223
-
|
|
ADC Linker
|
Cancer
|
|
MC-GGFG-NH-D-Lactic acid is a linker that can be used for the synthesis of JSSW-001 (HY-178217) .
|
-
-
- HY-W731085
-
|
|
ADC Linker
|
Cancer
|
|
MC-GGFG-NH-CH2-O-CH2-(s-cyclopropane)-COOH is an ADC linker that can be combined with the cytotoxic Camptothecin (HY-16560) to form an ADC-related drug-linker conjugate (Drug- Linker Conjugates for ADC).MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is conjugated to Camptothecin, which can further bind to the antibody Trastuzumab (HY-P9907) to form Antibody-Drug Conjugates (ADCs) .
|
-
-
- HY-400677
-
|
|
ADC Linker
|
Cancer
|
|
NH2-PEG4-GGFG-NH-CH2-O-CH2COOH is a reactant for the synthesis of ADC linkers and is used to synthesize Antibody-Drug Conjugates (ADCs) .
|
-
-
- HY-178260
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
LM-D01 is a Drug-Linker Conjugates for ADC. LM-D01 consists of the ADC Cytotoxin Exatecan-3-amine (HY-178265) and a linker MC-GGFG-NH-CH2-O-propionic acid (HY-178266). LM-D01 can be used for synthesis of ADCs .
|
-
-
- HY-172292
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cbz-GGFG-Bn is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
-
- HY-178266
-
|
|
ADC Linker
|
Cancer
|
|
MC-GGFG-NH-CH2-O-propionic acid is a ADC linker that can be used in the synthesis of LM-D01 (HY-178260) .
|
-
-
- HY-49929
-
|
|
ADC Linker
|
Cancer
|
|
MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is an ADC linker that can be combined with the cytotoxic Camptothecin (HY-16560) to form ADC-related drug-linker conjugates (Drug-Linker Conjugates for ADC ).MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is conjugated to Camptothecin, which can further bind to the antibody Trastuzumab (HY-P9907) to form Antibody-Drug Conjugates (ADCs) .
|
-
- HY-156810
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-PEG4-GGFG-CH2-O-CH2-Cbz is a cleavable ADC linker containing 4 units of PEG, which can be used to synthesize active antibody conjugation molecules (ADC) .
|
-
- HY-400676
-
|
|
ADC Linker
|
Cancer
|
|
NH2-PEG4-GGFG-CH2-O-CH2-Cbz is a reactant for the synthesis of ADC linker and is used to synthesize Antibody-Drug Conjugates (ADCs) .
|
-
- HY-46398
-
|
|
PROTAC Linkers
|
Cancer
|
|
Fmoc-Val-Phe-Boc is a PROTAC linker and a maleimide-GGFG peptide linker. Fmoc-Val-Phe-Boc can be used in the synthesis of the Deruxtecan .
|
-
- HY-176934
-
|
|
Drug Intermediate
|
Cancer
|
|
Belotecan-GFGG is an intermediate. Belotecan-GFGG can be used to synthesize the peptide conjugate MI-6PEG-GGFG-Belotecan. Belotecan-GFGG can be used in the research of the tumor microenvironment .
|
-
- HY-49453
-
|
|
PROTAC Linkers
|
Cancer
|
|
Fmoc-Gly-Gly-(D-Phe)-Gly-CH2-O-CH2-Cbz is a PROTAC linker and a maleimide-GGFG peptide linker. Fmoc-Gly-Gly-(D-Phe)-Gly-CH2-O-CH2-Cbz can be used in the synthesis of the Deruxtecan .
|
-
- HY-176415S1
-
|
Cys-MC-GGFG-Dxd-d5 TFA
|
Isotope-Labeled Compounds
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Cys-MC-GGFG-Dxd-d5 TFA (Cys-MC-GGFG-Dxd-d5 TFA) is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd-d5 TFA is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd-d5 TFA is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd-d5 TFA can be used in cancer research .
|
-
- HY-181185
-
|
|
ADC Linker
|
Others
|
|
MC-GGFG-3-Methylenecyclobutyl (compound L-7B) is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-181184
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-GGFG-3-Methylenecyclobutyl-Exatecan (Raludotatug-L-1-1) is a conjugate of the toxin molecule Exatecan (HY-13631) and the linker (HY-181185), and it can be used for the synthesis of ADC molecules .
|
-
- HY-185457
-
-
-
- HY-13631EG
-
|
MC-GGFG-DXD
|
蛍光色素
|
|
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
|
-
- HY-13631EG
-
|
MC-GGFG-DXD
|
生化学アッセイ試薬
|
|
Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
|
-
- HY-P3669
-
|
|
ADC Linker
Drug Intermediate
|
Cancer
|
|
Gly-Gly-Phe-Gly is a peptide spacer and can be applied to Doxorubicin (HY-15142A) (DXR) conjugates. Gly-Gly-Phe-Gly can be used as an ADC linker to synthesize ADCs, such as Puxitatug samrotecan (AZD 8205) (HY-171689) .
|
-
- HY-P1449
-
|
|
ADC Linker
|
Cancer
|
|
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).
|
-
- HY-136432
-
|
Mc-GGFG-PAB-OH
|
ADC Linker
|
Cancer
|
|
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) is a cleavable ADC linker used for antibody-drug conjugates (ADCs).
|
-
- HY-P4192
-
|
|
ADC Linker
|
Cancer
|
|
Fomc-Gly-Gly-Phe-Gly-OH (compound D5) can be used as an intermediate in the synthesis of ADC dual-drug-linker. Fomc-Gly-Gly-Phe-Gly-OH synthetic intermediate GGFGE further forms an important ADC dual-drug link assembly unit .
|
-
- HY-P11295
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-GGFG-PAB-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADC) .
|
-
- HY-136432A
-
|
Mc-GGFG-PAB-OH TFA
|
ADC Linker
|
Cancer
|
|
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) TFA is a cleavable ADC linker used for antibody-drug conjugates (ADCs).
|
-
- HY-P1449A
-
|
|
ADC Linker
|
Cancer
|
|
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).
|
-
- HY-13631ES4
-
|
|
|
Deruxtecan-d5 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
-
- HY-13631ES3
-
|
|
|
Deruxtecan-d2 is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
-
- HY-13631ES
-
|
|
|
Deruxtecan-d4 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
-
- HY-13631ES2
-
|
|
|
Deruxtecan-d4-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
|
-
-
- HY-13631ES1
-
|
|
|
Deruxtecan-d6 is the deuterium labeled Deruxtecan .
|
-
-
- HY-176415S
-
|
|
|
Cys-MC-GGFG-Dxd-d5 is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd can be used in cancer research .
|
-
-
- HY-176415S1
-
|
|
|
Cys-MC-GGFG-Dxd-d5 TFA (Cys-MC-GGFG-Dxd-d5 TFA) is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd-d5 TFA is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd-d5 TFA is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd-d5 TFA can be used in cancer research .
|
-
-
- HY-134723
-
|
|
|
DBCO
ADC Synthesis
|
|
DBCO-PEG4-GGFG-Dxd is a agent-linker conjugate for ADC with potent antitumor activity by using Dxd (a DNA topoisomerase I inhibitor), linked via the cleavable ADC linker DBCO-PEG4-GGFG . DBCO-PEG4-GGFG-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-147363
-
|
|
|
ADC Synthesis
DBCO
|
|
DIBAC-GGFG-NH2CH2-Dxd (compound LP4), a Camptothecin (HY-16560) derivative, is a linker-payload of protein-agent conjugates . Dxd (HY-13631D) can be used as a payload for the antibody-coupling drug ADC (DS-8201a).DIBAC-GGFG-NH2CH2-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .
|
入力情報は安全に管理されます. ※ 必須入力項目.
Inquiry Information
- 製品名:
- 製品番号:
- 数量:
- MCE 日本正規代理店: